A NARRATIVE review has revealed that obesity pharmacotherapy can deliver substantial pain relief in osteoarthritis, yet no evidence has shown that it modifies joint structure, so these drugs cannot currently be considered disease-modifying treatments.
Glucagon-like peptide-1 (GLP-1) receptor agonists and multi-agonists have become central to obesity care, and their emerging role in osteoarthritis management has attracted growing interest. Interpreting pain outcomes, structural joint effects, weight-loss quality, and time to total joint replacement (TJR) remains challenging, and it was unclear whether these drugs modified osteoarthritis or simply relieved symptoms through weight loss.
The authors conducted a narrative review of clinical and basic science literature on the relationships between obesity, osteoarthritis, and weight loss, focusing on GLP-1 therapies and emerging obesity medications. They examined randomised controlled trials, observational studies, translational investigations, and regulatory guidance documents, with emphasis on pain outcomes, structural joint effects, and factors influencing progression to TJR. The review also considered the importance of weight-loss quality and the patient populations most likely to benefit from current obesity pharmacotherapy.
Recent randomised controlled trials, primarily involving patients with osteoarthritis and class III obesity (body mass index above 40), demonstrated substantial pain reduction following obesity pharmacotherapy. Interpretation of these benefits was complicated by obesity-associated pain, multimorbidity, and limitations of patient-reported outcomes such as WOMAC. The evidence supported symptomatic improvement associated with weight loss, but it was unknown whether these agents directly modified osteoarthritis-related pain pathways or slowed structural progression. Reductions in fat mass could be accompanied by bone loss and reduced muscle mass, and patients with sarcopenia or elevated bone resorption were considered particularly vulnerable. Emerging concepts such as clinical obesity highlighted the biological heterogeneity of osteoarthritis populations and suggested that treatment responses might differ considerably between patients.
Without evidence of direct joint structural modification, obesity pharmacotherapy cannot currently be considered a disease-modifying osteoarthritis treatment, although it may set a new benchmark for pain management in selected patients living with obesity. Because weight loss does not necessarily translate to structural benefit, pain should not serve as a stand-alone outcome in future trials. Studies should evaluate structural outcomes, weight-loss quality, and patient heterogeneity so that these therapies deliver sustained symptomatic benefit without compromising musculoskeletal health.
Reference
Rombach J et al. Can obesity pharmacotherapy modify osteoarthritis? Interpreting pain relief, weight-loss quality, and structural outcomes. Osteoarthritis and Cartilage. 2026;DOI:10.1016/j.joca.2026.09.007.
Featured image: Kateryna on Adobe Stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
